Literature DB >> 9744572

Tumor cell resistance to topoisomerase II poisons: role for intracellular free calcium in the sensitization by inhibitors or calcium-calmodulin-dependent enzymes.

D R Grabowski1, G R Dubyak, L Rybicki, H Hidaka, R Ganapathi.   

Abstract

Tumor cell resistance to inhibitors of topoisomerase II (topo II) is associated frequently with the overexpression of P-glycoprotein (PGP), and strategies to overcome resistance are focused on restoring defects in drug accumulation. Inhibitors of calcium-calmodulin-dependent enzymes sensitize resistant tumor cells to the topo II poison etoposide (VP-16) by enhancing DNA damage and an apoptotic response. In the present study, we have investigated the consequences of buffering intracellular calcium with 1,2-bis(o-aminophenoxy)ethane-N,N,N'N'-tetraacetic acid tetra(acetoxy-methyl) ester (BAPTA-AM) on the sensitizing effects of the calmodulin-dependent protein kinase II inhibitor 1-[N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-piperazine (KN-62) in etoposide-resistant human leukemia HL-60 (HL-60/ADR0.05) cells. In cells pretreated with 20 microM BAPTA-AM for 2 hr, extracellular ATP failed to trigger intracellular calcium transients, and no effects on the accumulation of VP-16 were apparent. Also, the effect of KN-62 in significantly (P=0.002 to 0.042) enhancing the accumulation of VP-16 in HL-60/ADR0.05 cells was unaffected due to pretreatment with BAPTA-AM. In contrast, pretreatment with BAPTA-AM reduced the DNA damage induced by VP-16, and significantly (P=0.038) reversed the enhancement by KN-62 of VP-16-stabilized topo II-mediated DNA cleavable complex formation. The pretreatment of HL-60/ADR0.05 cells with BAPTA-AM was also associated with the hypophosphorylation of topo IIalpha. Consistent with the ability of BAPTA-AM to circumvent the potentiation by KN-62 of VP-16-induced DNA damage, survival of cells treated with 40 microM VP-16 in the absence of KN-62 and 10 microM VP-16 in the presence of KN-62 was significantly (P=0.026 to 0.031) higher due to BAPTA-AM pretreatment. Results demonstrate that intracellular calcium transients could play a key role in the sensitization of etoposide-resistant tumor cells by inhibitors of calcium-calmodulin-dependent enzymes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9744572     DOI: 10.1016/s0006-2952(98)00159-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

2.  Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs.

Authors:  Oliver Thews; Birgit Gassner; Debra K Kelleher; Gerald Schwerdt; Michael Gekle
Journal:  Neoplasia       Date:  2006-02       Impact factor: 5.715

3.  Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.

Authors:  M Aoyama; D R Grabowski; G R Dubyak; A I Constantinou; L A Rybicki; R M Bukowski; M K Ganapathi; I D Hickson; R Ganapathi
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

4.  Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).

Authors:  Lauren M Congdon; Alan Pourpak; Aluvia M Escalante; Robert T Dorr; Terry H Landowski
Journal:  Biochem Pharmacol       Date:  2007-11-04       Impact factor: 5.858

5.  Long-chain ceramide is a potent inhibitor of the mitochondrial permeability transition pore.

Authors:  Sergei A Novgorodov; Tatyana I Gudz; Lina M Obeid
Journal:  J Biol Chem       Date:  2008-07-02       Impact factor: 5.157

6.  Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.

Authors:  Gopalakrishnan Aridoss; Bo Zhou; David L Hermanson; Nicholas P Bleeker; Chengguo Xing
Journal:  J Med Chem       Date:  2012-05-23       Impact factor: 7.446

7.  Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.

Authors:  Beata M Gruber; Elzbieta L Anuszewska; Irena Bubko; Aneta Goździk; Izabela Fokt; Waldemar Priebe
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-06-08       Impact factor: 4.291

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.